Scientists Edge Closer Towards First Pancreatitis Treatment
News Jul 26, 2013
Each year around 20,000 people in the UK are admitted to hospital with acute pancreatitis. One in five of these cases are severe, resulting in around 1000 deaths annually.
Published in the US-based PNAS journal, findings reveal that tests undertaken by scientists at Cardiff University, using an existing calcium channel-blocking compound developed by GlaxoSmithKline, have succeeded in markedly reducing the flow of calcium into isolated pancreatic cells and stopping the root cause of the disease in its tracks.
“The aim of the research was to block excessive calcium entry caused by agents inducing pancreatitis and then test whether this would protect the pancreatic cells from self-digestion and death,” explains Senior Author of the research and Director of Cardiff University’s School of Biosciences, MRC Professor Ole Petersen FRS.
“Our research shows that the calcium channel inhibiting compound offers unique and effective protection against inappropriate activation inside the cells of digestive enzymes, which would cannibalise the pancreas and the surrounding tissue.
“This breakthrough shows huge potential to radically change and improve the outcome for patients suffering from severe pancreatitis. The publication of these findings will open the way for further research involving animals and humans – and, if successful, we shall for the first time be able to treat this often fatal disease.”
Tiny Kidneys: Building Better Models to Test DrugsNews
A free online kidney atlas built by USC researchers empowers stem cell scientists everywhere to generate more human-like tiny kidneys for testing new drugs and creating renal replacement therapies.READ MORE
Could Alzheimer's Drug Repair Brain Damage After Alcohol Binges?News
A drug used to slow cognitive decline in Alzheimer's disease could offer clues on how drugs might one day be able to reverse brain changes that affect learning and memory in teens and young adults who binge drink.READ MORE
Absolute Antibody and Kerafast Merge Increasing Access to Unique Reagents and Recombinant Antibody TechnologyNews
Absolute Antibody Ltd., and Kerafast Inc., have announced a merger of the two companies. The merger brings together two companies with a shared commitment to improving the selection of research tools available to the scientific community.READ MORE